Can ensidipine cure leukemia? Experts give authoritative answers!

Enasidenib is a targeted drug mainly used to treat acute myeloid leukemia (AML). In particular, ensidipine has been shown to have significant efficacy in leukemia patients who carry IDH2 mutations. IDH2 (isocitrate dehydrogenase 2) mutation is one of the common gene mutations in acute myeloid leukemia. It can lead to abnormal proliferation of leukemia cells and affect cell differentiation.

Although ensidipine has made important progress in the treatment of acute myeloid leukemia, it cannot yet completely "cure" leukemia. The mechanism of action of ensidipine is to restore the normal cell differentiation process by inhibiting the activity of IDH2-mutated isocitrate dehydrogenase, thereby slowing down the progression of leukemia. Clinical trials have shown that ensidipine can effectively induce remission of leukemia, providing a new treatment option especially for patients who cannot be effectively treated with traditional chemotherapy.

However, the efficacy of ensidipine is not 100%, and patient responses vary from individual to individual. Although some patients are able to achieve partial remission with ensidipine, most patients may still be at risk of disease recurrence. Current clinical data suggest that ensidipine is effective in many patients, but it does not imply a complete cure for leukemia. The duration of the effect, the durability of the effect, and the final outcome of the treatment may be affected by a variety of factors, including the patient's overall health, the type and mutation of the leukemia, etc.

In summary, ensidipine provides a new treatment option for patients with acute myeloid leukemia carrying IDH2 mutations, which can effectively improve treatment response and delay disease progression. However, although ensidipine has achieved good results, it still cannot "cure" leukemia, and patients may require long-term treatment and monitoring to deal with possible relapse.

Reference materials:https://www.idhifa.com/